Identification of 5-HT3 receptors on human platelets: Increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP)

Christian Stratz; Dietmar Trenk; Harsharan S. Bhatia; Christian Valina; Franz-Josef Neumann; Bernd L. Fiebich

doi:10.1160/TH07-10-0630

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(04): 784-786
DOI: 10.1160/TH07-10-0630

Letters to the Editor

Schattauer GmbH

Identification of 5-HT3 receptors on human platelets: Increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP)

Christian Stratz

¹Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany

,

Dietmar Trenk

¹Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany

,

Harsharan S. Bhatia

²Department of Psychiatry, University of Freiburg Medical School, Freiburg, Germany

,

Christian Valina

¹Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany

,

Franz-Josef Neumann

¹Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany

,

Bernd L. Fiebich

²Department of Psychiatry, University of Freiburg Medical School, Freiburg, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Li N, Wallen NH, Ladjevardi M. et al. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8: 517-523.
2 De Clerck F, Xhonneux B, Leysen J. et al. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984; 33: 2807-2811.
3 Cerrito F, Lazzaro MP, Gaudio E. et al. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 1993; 53: 209-215.
4 Fiebich BL, Akundi RS, Seidel M. et al. Expression of 5-HT3A receptors in cells of the immune system. Scand J Rheumatol. 2004 (Suppl) 9-11.
5 Fiebich BL, Akundi RS, Lieb K. et al. Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scand J Rheumatol. 2004 (Suppl) 28-32.
6 Vega LL, Munoz E, Calzado MA. et al. The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochem Pharmacol 2005; 70: 369-380.
7 Werner P, Kawashima E, Reid J. et al. Organization of the mouse 5-HT3 receptor gene and functional expression of two splice variants. Brain Res Mol Brain Res 1994; 26: 233-241.
8 Maricq AV, Peterson AS, Brake AJ. et al. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991; 254: 432-437.
9 Reeves DC, Lummis SC. The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel (review). Mol Membr Biol 2002; 19: 11-26.
10 Niesler B, Frank B, Kapeller J. et al. Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003; 310: 101-111.
11 Greenshaw AJ, Silverstone PH. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications. Drugs 1997; 53: 20-39.
12 Fatima SK. Effect of D-serine on the serotonin receptors of human platelets. Exp Brain Res 2006; 173: 353-356.
13 Weyrich A, Cipollone F, Mezzetti A. et al. Platelets in atherothrombosis: new and evolving roles. Curr Pharm Des 2007; 13: 1685-1691.
14 Steinhubl SR. Platelets as mediators of inflammation. Hematol Oncol Clin North Am 2007; 21: 115-121.
15 Michiels JJ, Gawaz M. Preface: platelets in inflammation and atherothrombosis. Semin Thromb Hemost 2007; 33: 119-122.
16 Schneider EM, Ma X, Stratz T. et al. Immunomodulatory function of the 5-HT3 receptor antagonist tropisetron. Scand J Rheumatol. 2004 (Suppl) 34-40.
17 Muller W, Fiebich BL, Stratz T. 5-HT3 receptor antagonists als analgetics in rheumatic diseases. Z Rheumatol 2006; 65 546 548-552.
18 Walther DJ, Peter JU, Winter S. et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003; 115: 851-862.
19 Berry CN, Lorrain J, Lochot S. et al. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist. Thromb Haemost 2001; 85: 521-528.